Summary and Investment Conclusions First DataBank and Medi-Span are the dominant providers of point-of-sale pricing information to US pharmacies. In December First DataBank announced it would provide National Average Drug…
Background – PCSK9 Inhibitors and New Cholesterol Treatment Guidelines Amgen and Sanofi / Regeneron presented phase III LDL-C (‘bad cholesterol’) lowering data for their respective PCSK9 inhibitors (evolocumab and alirocumab,…
We expect 1Q14 health services demand growth (y/y, nominal) of 3.4%, the product of 2.4% growth in intensity demand and 1.0% growth in nominal pricing (Exhibit 1). Our estimate of…
Summary and Conclusion Hospitals’ provisions for doubtful accounts have been rising (Exhibit 1); we believe this is in large part due to falling collection rates on the self-pay portion of…
We expect 1Q14 health services demand growth (y/y, nominal) of 3.6%, the product of 2.6% growth in intensity demand and 1.0% growth in nominal pricing (Exhibit 1). Our estimate of…
The age-mix of health insurance exchange (HIE) enrollees (Exhibit 1, green columns) skews older than the age-mix we believe is necessary (Exhibit 1, grey columns) to avoid adverse selection, i.e.…
Research Method and Key Findings We compared hospital networks for health plans sold on the Affordable Care Act’s (ACA’s) health insurance exchanges (HIEs) with hospital networks for comparable[1] plans sold…
Summary and Conclusions The prescription drug formularies of health plans sold on the Affordable Care Act’s (ACA’s) public health insurance exchanges (HIEs) are significantly more restrictive than the drug formularies…
*Please note a change in terminology in this report, as compared to previous versions. Until now we’ve referred to total health services demand as the product of units and pricing,…
Health insurance exchange (HIE) enrollment levels through December 28 remain quite low. States operating their own exchanges enrolled 1.0M persons, equivalent to 7.4% of these states’ adjusted uninsured populations (Exhibit…